Lisanti Capital Growth LLC Purchases New Holdings in Definium Therapeutics, Inc. $DFTX

Lisanti Capital Growth LLC purchased a new stake in Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 69,550 shares of the company’s stock, valued at approximately $2,647,000. Lisanti Capital Growth LLC owned 0.05% of Definium Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP bought a new position in Definium Therapeutics during the 2nd quarter worth $138,755,000. Seven Fleet Capital Management LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $6,992,000. Moody Aldrich Partners LLC grew its holdings in shares of Definium Therapeutics by 191.8% during the 3rd quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after purchasing an additional 97,845 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of Definium Therapeutics by 61.3% during the 3rd quarter. Alps Advisors Inc. now owns 178,006 shares of the company’s stock worth $6,775,000 after purchasing an additional 67,618 shares in the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth $1,592,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Latest Definium Therapeutics News

Investors following DFTX have been watching these news items:

• Positive Sentiment: Definium reported a third-quarter loss of $0.46 per share, narrower than analysts’ expected loss of $0.55. Commentary also points to clinical momentum following DT120 Phase 3 data, which may support investor interest in the pipeline. Third-quarter results DT120 analysis
• Neutral Sentiment: The company announced a planned webcast about its third-quarter results and presentations of DT120 Phase 3 data at the NEI Congress. These events may provide more information, but the announcements themselves do not report new trial findings. Planned webcast NEI Congress presentations
• Negative Sentiment: One analysis argues that the stock’s valuation looks inflated despite the potential for future approval. RBC also characterized the investment as carrying speculative risk, underscoring uncertainty around clinical development and commercialization. Valuation analysis

Analysts Set New Price Targets

DFTX has been the subject of several recent analyst reports. UBS Group reaffirmed a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Tuesday, September 15th. Canaccord Genuity Group set a $78.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Oppenheimer restated an “outperform” rating and issued a $75.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Finally, Bank of America assumed coverage on shares of Definium Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $66.24.

Definium Therapeutics Stock Performance

Definium Therapeutics stock opened at $34.47 on Thursday. Definium Therapeutics, Inc. has a 12-month low of $10.46 and a 12-month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 15.53 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average price is $36.31 and its two-hundred day moving average price is $30.23. The stock has a market cap of $4.63 billion, a PE ratio of -11.08 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Monday, November 9th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.09. As a group, analysts expect that Definium Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 31,550 shares of Definium Therapeutics stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the sale, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. The trade was a 1.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider owned 494,228 shares of the company’s stock, valued at approximately $18,073,917.96. This represents a 2.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 71,098 shares of company stock valued at $2,626,115. Company insiders own 2.40% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.